SCHEMBL16907476

SCHEMBL16907476

CC(C)(C)OC(=O)N1CCC(c2cc(NC(=O)Oc3ccccc3)cc(C(F)(F)F)c2)CC1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ NAMPT P43490 1/20 0.52
▸ P2RY14 Q15391 1/20 0.47
▸ TACR1 P25103 3/20 0.47
▸ STS P08842 1/20 0.46
▸ GPR119 Q8TDV5 1/20 0.45
▸ MAPT P10636 2/20 0.45
▸ POLB P06746 1/20 0.45
▸ JAK3 P52333 3/20 0.44
▸ PTK2 Q05397 3/20 0.44
▸ JAK2 O60674 2/20 0.44
▸ BRAF P15056 1/20 0.44
▸ KDR P35968 1/20 0.44
▸ TGFBR1 P36897 1/20 0.42
▸ USP30 Q70CQ3 1/20 0.42
▸ PTPN2 P17706 1/20 0.42
▸ PTPN1 P18031 1/20 0.42
▸ PTPN6 P29350 1/20 0.42
▸ DDB1 Q16531 1/20 0.42
▸ CRBN Q96SW2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16895230 0.88 PTPN2 (0.55) P2RY14TACR1STSGPR119MAPT
SCHEMBL16907601 0.86 KDR (0.54) P2RY14MAPTBRAFKDR
SCHEMBL25567301 0.86 NAMPT (0.69) NAMPTGPR119MAPTJAK3PTK2
SCHEMBL29537824 0.81 NAMPT (0.60) NAMPTGPR119MAPTUSP30PTPN2
SCHEMBL1988842 0.81 NAMPT (0.60) NAMPTGPR119MAPTUSP30PTPN2
SCHEMBL1988843 0.81 NAMPT (0.60) NAMPTGPR119MAPTUSP30PTPN2
SCHEMBL16895191 0.80 USP30 (0.49) TACR1STSMAPTPOLBBRAF
SCHEMBL16907507 0.78 RXFP1 (0.52) TACR1MAPTPOLB
SCHEMBL16895197 0.78 TACR1 (0.45) NAMPTTACR1MAPTBRAFKDR
SCHEMBL16907431 0.78 NPSR1 (0.59) POLBUSP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9840477-B2 Cyclopropanecarboxamido-substituted aromatic compounds as anti-tumor agents CB THERAPEUTICS INC. (KY) 2017-12-12 — — US disclosed
US-20160280664-A1 Cyclopropanecarboxamido-Substituted Aromatic Compounds as Anti-tumor Agents APOLLOMICS INC. 2016-09-29 — — US disclosed
US-9359338-B2 Cyclopropanecarboxamido-substitute aromatic compounds as anti-tumor agents CROWN BIOSCIENCE INC. (TAIWAN) (TW) 2016-06-07 — — US disclosed
US-20150197511-A1 CYCLOPROPANECARBOXAMIDO-SUBSTITUTE AROMATIC COMPOUNDS AS ANTI-TUMOR AGENTS APOLLOMICS INC. 2015-07-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160280664-A1 Cyclopropanecarboxamido-Substituted Aromatic Compounds as Anti-tumor Agents BRAF, RAF1, ARAF NAMPT 2787/4885P2RY14 3248/4885TACR1 4179/4885
US-20150197511-A1 CYCLOPROPANECARBOXAMIDO-SUBSTITUTE AROMATIC COMPOUNDS AS ANTI-TUMOR AGENTS BRAF, ARAF, RAF1 NAMPT 2384/4885P2RY14 3145/4885TACR1 3711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback